DexCom Statistics
Share Statistics
DexCom has 392.11M
shares outstanding. The number of shares has increased by -1.74%
in one year.
| Shares Outstanding | 392.11M |
| Shares Change (YoY) | -1.74% |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | 90.33% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,755 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 11.41M, so 2.91% of the outstanding
shares have been sold short.
| Short Interest | 11.41M |
| Short % of Shares Out | 2.91% |
| Short % of Float | 3.73% |
| Short Ratio (days to cover) | 3.25 |
Valuation Ratios
The PE ratio is 54.61 and the forward
PE ratio is 33.95.
DexCom's PEG ratio is
39.32.
| PE Ratio | 54.61 |
| Forward PE | 33.95 |
| PS Ratio | 7.8 |
| Forward PS | 4.3 |
| PB Ratio | 14.97 |
| P/FCF Ratio | 49.89 |
| PEG Ratio | 39.32 |
Financial Ratio HistoryEnterprise Valuation
DexCom has an Enterprise Value (EV) of 33.45B.
| EV / Sales | 8.29 |
| EV / EBITDA | 35.37 |
| EV / EBIT | 33.8 |
| EV / FCF | 53.03 |
Financial Position
The company has a current ratio of 1.47,
with a Debt / Equity ratio of 1.23.
| Current Ratio | 1.47 |
| Quick Ratio | 1.28 |
| Debt / Equity | 1.23 |
| Debt / EBITDA | 2.74 |
| Debt / FCF | 4.1 |
| Interest Coverage | 31.58 |
Financial Efficiency
Return on Equity is 27.4% and Return on Invested Capital is 10.2%.
| Return on Equity | 27.4% |
| Return on Assets | 8.89% |
| Return on Invested Capital | 10.2% |
| Revenue Per Employee | $395,392.16 |
| Profits Per Employee | $56,490.2 |
| Employee Count | 10,200 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 2.89 |
Taxes
| Income Tax | 132.8M |
| Effective Tax Rate | 18.73% |
Stock Price Statistics
The stock price has increased by -33.31% in the
last 52 weeks. The beta is 1.44, so DexCom's
price volatility has been higher than the market average.
| Beta | 1.44 |
| 52-Week Price Change | -33.31% |
| 50-Day Moving Average | 72.26 |
| 200-Day Moving Average | 75.2 |
| Relative Strength Index (RSI) | 71.63 |
| Average Volume (20 Days) | 4,592,963 |
Income Statement
In the last 12 months, DexCom had revenue of 4.03B
and earned 576.2M
in profits. Earnings per share was 1.46.
| Revenue | 4.03B |
| Gross Profit | 2.47B |
| Operating Income | 600M |
| Net Income | 576.2M |
| EBITDA | 945.7M |
| EBIT | 728M |
| Earnings Per Share (EPS) | 1.46 |
Full Income StatementBalance Sheet
The company has 606.1M in cash and 2.59B in
debt, giving a net cash position of -1.98B.
| Cash & Cash Equivalents | 606.1M |
| Total Debt | 2.59B |
| Net Cash | -1.98B |
| Retained Earnings | 1.6B |
| Total Assets | 6.75B |
| Working Capital | 1.52B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 989.5M
and capital expenditures -358.8M, giving a free cash flow of 630.7M.
| Operating Cash Flow | 989.5M |
| Capital Expenditures | -358.8M |
| Free Cash Flow | 630.7M |
| FCF Per Share | 1.56 |
Full Cash Flow StatementMargins
Gross margin is 61.14%, with operating and profit margins of 14.88% and 14.29%.
| Gross Margin | 61.14% |
| Operating Margin | 14.88% |
| Pretax Margin | 17.58% |
| Profit Margin | 14.29% |
| EBITDA Margin | 23.45% |
| EBIT Margin | 14.88% |
| FCF Margin | 15.64% |
